David George, MD
Ophthalmology · Parkersburg, WVNPI 1619945755
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (46.4%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. 17 manufacturers reported payments, led by Alcon Research LLC at 43.6% of the total. Reporting peaked in 2019 at $4,955 and has fallen 93.6% since, to $318 in 2025. Among ophthalmology clinicians in WV with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 108 payments — averaging $66.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alcon Research LLC$3K
- Alcon$2K
- AbbVie$870
- Johnson & Johnson Surgical Vision, Inc.$667
- Rxsight Inc$172
- Bausch & Lomb, A Division Of Bausch Health US, LLC$156
- plus $393 from 11 others
What the payments were for
- Consulting fees$3,15044%
- Travel & lodging$72110%
- Food & beverage$3,35146%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alcon Research LLC | 4 | $3,150 |
| Alcon | 32 | $1,813 |
| AbbVie(2 entities) | 19 | $870 |
| Johnson & Johnson Surgical Vision, Inc. | 27 | $667 |
| Rxsight Inc | 4 | $172 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 2 | $156 |
| Glaukos Corporation | 2 | $120 |
| Bausch & Lomb Americas Inc. | 3 | $43 |
| Oyster Point Pharma, Inc. | 3 | $43 |
| Sun Pharmaceutical Industries Inc. | 2 | $37 |
| Shire North American Group Inc | 2 | $35 |
| Novartis | 2 | $28 |
| Aerie Pharmaceuticals, Inc. | 2 | $27 |
| Johnson & Johnson | 1 | $21 |
| Harrow Eye, LLC | 1 | $16 |
| Biotissue Holdings Inc. | 1 | $12 |
| Kala Pharmaceuticals, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$7,221 in reported general payments places this provider in the 90th percentile of 85 ophthalmology providers in West Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 134 | $107,693 |
| Prednisolone Acetate | 1,751 | $52,902 |
| RocklatanNetarsudil Mesylat/Latanoprost | 67 | $29,681 |
| MoxifloxacinMoxifloxacin Hcl | 1,072 | $22,959 |
| LumiganBimatoprost | 41 | $22,424 |
| CombiganBrimonidine Tartrate/Timolol | 49 | $16,775 |
| XiidraLifitegrast | 18 | $16,091 |
| Ketorolac Tromethamine | 1,061 | $15,288 |
| RhopressaNetarsudil Mesylate | 30 | $13,648 |
| Cyclosporine | 28 | $12,670 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 73 | $11,228 |
| Latanoprost | 943 | $9,161 |
| Timolol Maleate | 432 | $6,612 |
| Travoprost | 45 | $6,366 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 179 | $3,224 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Lumigan, Combigan | $870 | $146,892224 claims |
| Aerie Pharmaceuticals, Inc.Rocklatan, Rhopressa | $27 | $43,32997 claims |
| Bausch & Lomb Americas Inc.Xiidra | $43 | $16,09118 claims |
| AlconSimbrinza | $1,813 | $2,62213 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 85 ophthalmology providers in West Virginia.
Other ophthalmology in Parkersburg
- Zane LazerParkersburg$1K
- Scott StricklerParkersburg$894
- Anthony RealiniMorgantown$410K
- Vishal VermaHuntington$159K
- Joseph SinclairCharleston$9K
- Brian GriffithCharleston$9K
- Stephen CassisMadison$8K
- Jason LudlowCharleston$8K
- Brian McMillanMorgantown$8K
- Lawrence MinardiCharleston$7K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.